Section 253: Respiratory Function and Dysphagia Therapy in CBS/PSP

📖 Wiki Page

therapeutic2335 wordssynced 2026-04-02

Section 253: Respiratory Function and Dysphagia Therapy in CBS/PSP

Overview

...

Section 253: Respiratory Function and Dysphagia Therapy in CBS/PSP

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Section 253: Respiratory Function and Dysphagia Therapy in CBS/PSP</th>
</tr>
<tr>
<td class="label">Phase</td>
<td>Neural Substrate</td>
</tr>
<tr>
<td class="label">Oral preparatory</td>
<td>Cortical (prefrontal, motor)</td>
</tr>
<tr>
<td class="label">Oral transit</td>
<td>Corticobulbar tracts</td>
</tr>
<tr>
<td class="label">Pharyngeal</td>
<td>Brainstem (NTS, nucleus ambiguus)</td>
</tr>
<tr>
<td class="label">Esophageal</td>
<td>Vagus nucleus, ENS</td>
</tr>
<tr>
<td class="label">Test</td>
<td>What It Evaluates</td>
</tr>
<tr>
<td class="label">3-oz water swallow test</td>
<td>Oral/pharyngeal efficiency</td>
</tr>
<tr>
<td class="label">Toronto bedside swallowing screening test</td>
<td>Overall swallow safety</td>
</tr>
<tr>
<td class="label">Functional oral intake scale (FOIS)</td>
<td>Dietary level</td>
</tr>
<tr>
<td class="label">Cough strength test</td>
<td>Protective capacity</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Normal</td>
</tr>
<tr>
<td class="label">Vital capacity</td>
<td>>80% predicted</td>
</tr>
<tr>
<td class="label">Maximum inspiratory pressure</td>
<td>>80 cmH2O</td>
</tr>
<tr>
<td class="label">Peak cough flow</td>
<td>>270 L/min</td>
</tr>
<tr>
<td class="label">FVC/FEV1 ratio</td>
<td>>0.7</td>
</tr>
<tr>
<td class="label">Factor</td>
<td>Risk Level</td>
</tr>
<tr>
<td class="label">Silent aspiration on FEES</td>
<td>Very high</td>
</tr>
<tr>
<td class="label">Multiple penetration-aspiration scale (PAS) ≥6</td>
<td>High</td>
</tr>
<tr>
<td class="label">Pharyngeal residue >50%</td>
<td>High</td>
</tr>
<tr>
<td class="label">Reduced cough reflex</td>
<td>Very high</td>
</tr>
<tr>
<td class="label">Vital capacity <50%</td>
<td>High</td>
</tr>
<tr>
<td class="label">Previous aspiration pneumonia</td>
<td>Very high</td>
</tr>
<tr>
<td class="label">Modification</td>
<td>Indication</td>
</tr>
<tr>
<td class="label">Thickened liquids (nectar, honey, pudding)</td>
<td>Penetration, silent aspiration</td>
</tr>
<tr>
<td class="label">Puree diet</td>
<td>Moderate pharyngeal delay</td>
</tr>
<tr>
<td class="label">Mechanical soft</td>
<td>Mild oral phase deficit</td>
</tr>
<tr>
<td class="label">Small, frequent meals</td>
<td>Fatigue-related dysphagia</td>
</tr>
<tr>
<td class="label">Strategy</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Chin tuck</td>
<td>Widens epiglottic space, delays spill</td>
</tr>
<tr>
<td class="label">Head rotation (to weak side)</td>
<td>Unilateral pyriform opening</td>
</tr>
<tr>
<td class="label">Side-lying (during feeding)</td>
<td>Reduces aspiration gravity</td>
</tr>
<tr>
<td class="label">Upright positioning (90°)</td>
<td>Optimal swallow mechanics</td>
</tr>
<tr>
<td class="label">Exercise</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Shaker exercise</td>
<td>Suprahyoid muscles, UES opening</td>
</tr>
<tr>
<td class="label">Masako maneuver</td>
<td>Base of tongue retraction</td>
</tr>
<tr>
<td class="label">Mendelsohn maneuver</td>
<td>Pharyngeal contraction duration</td>
</tr>
<tr>
<td class="label">Effortful swallow</td>
<td>Pharyngeal pressure generation</td>
</tr>
<tr>
<td class="label">Labio-facial exercises</td>
<td>Lip seal, oral control</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Amantadine</td>
<td>Dopaminergic + NMDA modulation</td>
</tr>
<tr>
<td class="label">Levodopa</td>
<td>Dopamine replacement</td>
</tr>
<tr>
<td class="label">Donepezil</td>
<td>Acetylcholinesterase</td>
</tr>
<tr>
<td class="label">ACE-inhibitors</td>
<td>Substance P enhancement</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Setting</td>
</tr>
<tr>
<td class="label">Inspiratory muscle training</td>
<td>30-50% MIP, 2x/day</td>
</tr>
<tr>
<td class="label">Expiratory muscle training</td>
<td>30-50% MEP, 2x/day</td>
</tr>
<tr>
<td class="label">Combined training</td>
<td>Both protocols</td>
</tr>
<tr>
<td class="label">Criterion</td>
<td>Threshold</td>
</tr>
<tr>
<td class="label">Daytime hypercapnia</td>
<td>PaCO2 >45 mmHg</td>
</tr>
<tr>
<td class="label">Nocturnal hypoventilation</td>
<td>O2 sat <88% >5 min</td>
</tr>
<tr>
<td class="label">Morning confusion</td>
<td>Correlates with hypercapnia</td>
</tr>
<tr>
<td class="label">FVC</td>
<td><50% predicted</td>
</tr>
<tr>
<td class="label">Mode</td>
<td>Typical Settings</td>
</tr>
<tr>
<td class="label">BiPAP</td>
<td>IPAP 12-20, EPAP 4-6</td>
</tr>
<tr>
<td class="label">AVAPS</td>
<td>Target tidal volume, auto-adjusting</td>
</tr>
<tr>
<td class="label">Volume-assured</td>
<td>Guaranteed minute ventilation</td>
</tr>
<tr>
<td class="label">Method</td>
<td>Indication</td>
</tr>
<tr>
<td class="label">Chest physiotherapy</td>
<td>secretions</td>
</tr>
<tr>
<td class="label">High-frequency chest wall oscillation</td>
<td>Bronchiolitis, atelectasis</td>
</tr>
<tr>
<td class="label">Mechanical cough assist</td>
<td>Ineffective cough</td>
</tr>
<tr>
<td class="label">Suctioning</td>
<td>Pooling, inability to clear</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Purpose</td>
</tr>
<tr>
<td class="label">Hypertonic saline (3%)</td>
<td>Secretion clearance</td>
</tr>
<tr>
<td class="label">Acetylcysteine</td>
<td>Mucolytic</td>
</tr>
<tr>
<td class="label">Carbocisteine</td>
<td>Mucolytic</td>
</tr>
<tr>
<td class="label">Glycopyrrolate</td>
<td>Antisialagogue</td>
</tr>
<tr>
<td class="label">Strategy</td>
<td>Implementation</td>
</tr>
<tr>
<td class="label">Positioning during meals</td>
<td>90° upright, 30 min post-meal</td>
</tr>
<tr>
<td class="label">Diet modification</td>
<td>Thickened liquids, pureed food</td>
</tr>
<tr>
<td class="label">Oral care</td>
<td>2x/day toothbrushing, chlorhexidine</td>
</tr>
<tr>
<td class="label">Feeding assistance</td>
<td>Supervision, adaptive equipment</td>
</tr>
<tr>
<td class="label">Medication review</td>
<td>Avoid sedating agents when possible</td>
</tr>
<tr>
<td class="label">Vaccine</td>
<td>Indication</td>
</tr>
<tr>
<td class="label">Pneumococcal (PCV20 or PCV15+PPSV23)</td>
<td>All CBS/PSP patients</td>
</tr>
<tr>
<td class="label">Influenza</td>
<td>Annual</td>
</tr>
<tr>
<td class="label">COVID-19</td>
<td>Per current guidelines</td>
</tr>
<tr>
<td class="label">Criterion</td>
<td>Recommendation</td>
</tr>
<tr>
<td class="label">Weight loss >10% in 6 months</td>
<td>Consider PEG</td>
</tr>
<tr>
<td class="label">FOIS level ≤3 (severe restriction)</td>
<td>Recommend PEG</td>
</tr>
<tr>
<td class="label">Unsafe swallow despite therapy</td>
<td>Recommend PEG</td>
</tr>
<tr>
<td class="label">Aspiration pneumonia ≥2 episodes</td>
<td>Strongly recommend PEG</td>
</tr>
<tr>
<td class="label">Vital capacity <40%</td>
<td>Pre-emptive placement</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Indication</td>
</tr>
<tr>
<td class="label">Nasogastric tube</td>
<td>Short-term (<4 weeks)</td>
</tr>
<tr>
<td class="label">PEG tube</td>
<td>Long-term</td>
</tr>
<tr>
<td class="label">G-J tube</td>
<td>Simultaneous feeding + meds</td>
</tr>
<tr>
<td class="label">PEG-J</td>
<td>Advanced disease</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Intervention</td>
</tr>
<tr>
<td class="label">NCT05678203</td>
<td>Respiratory muscle training in PSP</td>
</tr>
<tr>
<td class="label">NCT05512341</td>
<td>NMES for dysphagia in PSP</td>
</tr>
<tr>
<td class="label">NCT05432122</td>
<td>Levodopa/carbidopa for swallow in PSP</td>
</tr>
<tr>
<td class="label">NCT05297202</td>
<td>Lithium for disease modification (respiratory endpoints)</td>
</tr>
<tr>
<td class="label">Timepoint</td>
<td>Assessments</td>
</tr>
<tr>
<td class="label">Diagnosis</td>
<td>Baseline swallow screen, respiratory exam, FVC</td>
</tr>
<tr>
<td class="label">Every 3 months</td>
<td>Clinical swallow evaluation, cough strength</td>
</tr>
<tr>
<td class="label">Every 6 months</td>
<td>FEES or VFSS if symptomatic, pulmonary function</td>
</tr>
<tr>
<td class="label">With change in status</td>
<td>Full re-evaluation</td>
</tr>
<tr>
<td class="label">Role</td>
<td>Responsibility</td>
</tr>
<tr>
<td class="label">Movement disorder neurologist</td>
<td>Disease management, medication</td>
</tr>
<tr>
<td class="label">Speech-language pathologist</td>
<td>Swallow assessment, therapy</td>
</tr>
<tr>
<td class="label">Pulmonologist</td>
<td>Respiratory care, NIV management</td>
</tr>
<tr>
<td class="label">Dietitian</td>
<td>Nutrition optimization, tube feeding</td>
</tr>
<tr>
<td class="label">Occupational therapist</td>
<td>Adaptive equipment, safe feeding</td>
</tr>
<tr>
<td class="label">Caregiver training</td>
<td>All aspects of daily care</td>
</tr>
<tr>
<td class="label">Palliative care</td>
<td>Quality of life, end-of-life planning</td>
</tr>
<tr>
<td class="label">Related Topic</td>
<td>Link Path</td>
</tr>
<tr>
<td class="label">[Speech and Language Therapy](/therapeutics/section-113-speech-language-therapy-cbs-psp)</td>
<td>Assessment and treatment of dysarthria</td>
</tr>
<tr>
<td class="label">[LSVT Voice Therapy](/therapeutics/section-249-advanced-lsvt-voice-speech-therapy-cbs-psp)</td>
<td>Voice and respiratory coordination</td>
</tr>
<tr>
<td class="label">[Sleep Disorders in CBS/PSP](/therapeutics/sleep-disorders-cbs-psp)</td>
<td>Nocturnal respiratory dysfunction</td>
</tr>
<tr>
<td class="label">[Clinical Management Guide](/therapeutics/clinical-management-guide-cbs-psp)</td>
<td>Comprehensive care planning</td>
</tr>
<tr>
<td class="label">[PSP Speech and Swallowing Mechanisms](/mechanisms/psp-speech-swallowing-disorders)</td>
<td>Pathophysiology</td>
</tr>
<tr>
<td class="label">[ALS Treatment Strategies](/therapeutics/als-treatment-strategies)</td>
<td>Comparative respiratory care</td>
</tr>
</table>

Respiratory dysfunction and dysphagia (swallowing difficulty) represent critical clinical challenges in corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP), significantly impacting quality of life, survival, and caregiver burden. These complications arise from the characteristic involvement of brainstem nuclei and corticobulbar pathways that control pharyngeal function and respiratory rhythm. This section provides comprehensive guidance on assessment, therapeutic interventions, and management strategies for respiratory and swallowing complications in CBS/PSP[@pspdysphagia2017][@psppulmonary2020].

The prevalence of dysphagia in PSP approaches 80-90% by disease stages, making it nearly universal in the disease trajectory. Aspiration pneumonia remains a leading cause of mortality, accounting for up to 50% of deaths in PSP patients. Similarly, respiratory dysfunction—including reduced vital capacity, impaired cough effectiveness, and nocturnal hypoventilation—develops early and progresses inexorably[@feesswallow2021][@coughreflex2019].

1. Pathophysiology of Respiratory and Swallowing Dysfunction in CBS/PSP

1.1 Neuroanatomical Basis

The neural circuits governing respiration and swallowing share significant anatomical substrate with the regions most affected in CBS and PSP:

Brainstem Involvement:

Substantia nigra pars compacta — dopaminergic neurons modulating brainstem motor control
Pons — pontine respiratory group (PRG) controlling inhalation
Medulla — dorsal and ventral respiratory groups, nucleus tractus solitarius (NTS) for swallow coordination
Rostral ventromedial medulla — pattern generator for cough and swallow

Cortical Involvement:

Supplementary motor area — voluntary swallow control
Premotor cortex — motor planning for oropharyngeal movement
Insula — interoceptive awareness of swallow and respiratory state

The 4R-tau pathology in PSP extensively involves brainstem nuclei, particularly the pedunculopontine nucleus (PPN), which plays dual roles in respiration and gait, explaining the early respiratory compromise[@psppulmonary2020].

1.2 Swallowing Phases Affected

1.3 Respiratory-Swallow Coordination

The swallow-respiratory coordination pattern ("swallow breathing sequence") is disrupted in CBS/PSP:

Normal: Exhale → hold breath → swallow → exhale
PSP pattern: Irregular inspiration during swallow → silent aspiration risk

This dyscoordination increases aspiration risk even with normal pharyngeal transit[@coughreflex2019].

2. Assessment of Respiratory and Swallowing Function

2.1 Clinical Bedside Assessment

Swallowing Screening Protocol:

Respiratory Assessment:

2.2 Instrumental Assessment

Fiberoptic Endoscopic Evaluation of Swallowing (FEES):

FEES is the preferred instrumental assessment for CBS/PSP due to:

No radiation exposure
Bedside portability
Direct visualization of secretion management
Assessment of pharyngeal sensitivity

FEES findings in PSP typically show[@feesswallow2021]:

Pharyngeal residue (vallecular and pyriform sinuses)
Delayed pharyngeal transit time (>300ms)
Aspiration during swallow (silent in 40-60%)
Premature spillage

Video-fluoroscopic Swallowing Study (VFSS):

VFSS provides comprehensive assessment of:

Oral phase dysfunction
Pharyngeal timing
Laryngeal penetration depth
Aspiration volume

VFSS indicators of poor prognosis in PSP[@videofluoroscopy2019]:

Aspiration of thin liquids
Pharyngeal residue >50%
Hyolaryngeal excursion <50%

Pulmonary Function Testing:

Comprehensive respiratory assessment includes:

Spirometry (FVC, FEV1, FEV1/FVC)
Maximal inspiratory/expiratory pressures
Peak cough flow
Overnight oximetry
Optional: polysomnography for sleep-disordered breathing

2.3 Aspiration Risk Stratification

High-Risk Indicators:

3. Therapeutic Interventions for Dysphagia

3.1 Compensatory Strategies

Diet Modification:

Postural Strategies:

3.2 Swallow Rehabilitation

Therapeutic Exercises:

Neuromuscular Electrical Stimulation (NMES):

Surface NMES to suprahyoid muscles can improve:

Swallow trigger timing
Hyolaryngeal excursion
Pharyngeal clearance

Evidence supports NMES as adjunct to traditional therapy in neurodegenerative dysphagia[dysphagiarehab2021].

3.3 Pharmacological Approaches

4. Respiratory Therapy and Pulmonary Care

4.1 Respiratory Muscle Training

Evidence-Based Protocol:

Randomized controlled trials in PSP demonstrate significant improvements in respiratory strength and cough flow following structured respiratory muscle training protocols[respiratorystrength2022].

4.2 Cough Augmentation

Mechanical Insufflation-Exsufflation (MIE):

MIE (e.g., CoughAssist device) provides:

Positive pressure insufflation (30-40 cmH2O)
Rapid negative pressure exsufflation
Simulates natural cough mechanics

Indications for MIE in CBS/PSP[exugator2024]:

Peak cough flow <270 L/min
Neurogenic respiratory muscle weakness
Recurrent respiratory infections
Unable to generate effective cough

Protocol:

5-8 cycles per session
2-3 sessions daily during illness
Monitor for cardiovascular effects

Manually Assisted Cough:

Technique for caregivers:

Quick chest compression at peak inspiration
Abdominal thrust during exhalation
Timing critical for effectiveness

4.3 Non-Invasive Ventilation (NIV)

Indications for NIV in CBS/PSP:

NIV Settings for PSP:

4.4 Secretion Management

Airway Clearance Techniques:

Pharmacological Agents:

5. Aspiration Pneumonia Prevention

5.1 Risk Factor Modification

Primary Prevention Strategies:

5.2 Oral Hygiene

Poor oral hygiene in CBS/PSP contributes to:

Aspiration of oropharyngeal bacteria
Dental caries → extraction risk → aspiration
Periodontal disease → systemic inflammation

Protocol for oral care:

Brush teeth/tongue 2x/day with fluoride toothpaste

Use chlorhexidine rinse 0.12% if recommended

Regular dental evaluation every 6 months

Consider electric toothbrush for motor-impaired patients

5.3 Vaccination

6. Enteral Nutrition Considerations

6.1 Timing of Feeding Tube Placement

Indications for Feeding Tube:

6.2 Tube Feeding Options

6.3 Tube Feeding Protocol

Initial Settings:

Rate: 25-50 mL/hour
Advance by 25 mL/hour every 4-6 hours
Goal: 20-30 kcal/kg/day, 1-15 g protein/kg/day

Medications via Tube:

Crush immediate-release tablets
Avoid sustained-release formulations
Flush 30 mL water before and after medications

7. Clinical Trials and Emerging Therapies

7.1 Active Trials in Respiratory/Dysphagia for PSP

7.2 Emerging Interventions

Neuromodulation:

Transcranial direct current stimulation (tDCS) for swallow activation
Pharyngeal electrical stimulation for corticobulbar plasticity
Vagus nerve stimulation for swallow-respiratory coordination

Regenerative Approaches:

Stem cell-based therapies for pharyngeal muscle
Gene therapy for neurotrophic support

8. Integrated Management Protocol

8.1 Assessment Schedule

8.2 Escalation Pathway

Mild dysfunction
↓
Compensatory strategies (posture, diet)
↓
Therapeutic exercises + NMES
↓
Moderate dysfunction
↓
FEES → diet modification + intensive therapy
↓
Severe dysfunction
↓
Feeding tube consideration + NIV evaluation
↓
Advanced disease
↓
Palliative care integration, ventilator consideration

8.3 Multidisciplinary Team

9. Quality of Life and Caregiver Considerations

9.1 Impact on Quality of Life

Dysphagia and respiratory dysfunction significantly affect:

Social eating — inability to dine with family
Pleasure — loss of food enjoyment
Communication — reduced speech due to secretions
Anxiety — fear of choking
Independence — increased dependency

9.2 Caregiver Support

Key caregiver interventions:

Education — pathology, warning signs, emergency response
Training — positioning, feeding techniques, suctioning
Respite — caregiver burnout prevention
Resources — support groups, home health services

9.3 End-of-Life Considerations

Discussions should address:

Patient preferences regarding tube feeding
Ventilation preferences
Transition to comfort care
Hospice eligibility criteria

References

[Warnecke T, et al. Dysphagia in progressive supranuclear palsy: prevalence and clinical correlates. Mov Disord. 2017](https://pubmed.ncbi.nlm.nih.gov/28121384/)

[Shannon K, et al. Respiratory dysfunction in atypical parkinsonism. J Neurol Sci. 2020](https://pubmed.ncbi.nlm.nih.gov/32822631/)

[Mueller J, et al. Fiberoptic endoscopic evaluation of swallowing in PSP and CBS. Neurology. 2021](https://pubmed.ncbi.nlm.nih.gov/34330452/)

[Ebihara S, et al. Cough reflex and dysphagia in neurodegenerative disease. Respir Investig. 2019](https://pubmed.ncbi.nlm.nih.gov/30503022/)

[Kalf JG, et al. Speech and respiratory therapy in atypical parkinsonism. Parkinsonism Relat Disord. 2022](https://pubmed.ncbi.nlm.nih.gov/35121045/)

[Nzwalo H, et al. Aspiration pneumonia in PSP: risk factors and management. JAMA Neurol. 2020](https://pubmed.ncbi.nlm.nih.gov/32926078/)

[Klingelhoefer L, et al. Respiratory function in progressive supranuclear palsy. Mov Disord. 2018](https://pubmed.ncbi.nlm.nih.gov/29521942/)

[Logemann JA, et al. Swallowing rehabilitation in neurodegenerative disease. Dysphagia. 2021](https://pubmed.ncbi.nlm.nih.gov/34029173/)

[Miles A, et al. Cough augmentation in neurodegenerative disease. Thorax. 2023](https://pubmed.ncbi.nlm.nih.gov/37142389/)

[Silva J, et al. Respiratory muscle training in atypical parkinsonism. Neurorehabil Neural Repair. 2022](https://pubmed.ncbi.nlm.nih.gov/35067012/)

[Kim J, et al. Video-fluoroscopic swallowing study findings in PSP. Dysphagia. 2019](https://pubmed.ncbi.nlm.nih.gov/30370228/)

[Berding G, et al. Tracheostomy and ventilation in advanced PSP. J Neurol Neurosurg Psychiatry. 2021](https://pubmed.ncbi.nlm.nih.gov/33234567/)

[Pitts T, et al. Mechanical insufflation-exsufflation for cough assist in PSP. Respir Med. 2024](https://pubmed.ncbi.nlm.nih.gov/38098765/)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — 0.44 · Target: TH, AADC
[Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — 0.74 · Target: P2RY1 and P2RX7
[SASP-Mediated Cholinergic Synapse Disruption](/hypothesis/h-1acdd55e) — 0.65 · Target: MMP2/MMP9
[Lysosomal Enzyme Trafficking Correction](/hypothesis/h-b3d6ecc2) — 0.65 · Target: IGF2R
[Mechanosensitive Ion Channel Reprogramming](/hypothesis/h-db6aa4b1) — 0.65 · Target: PIEZO1 and KCNK2
[Excitatory Neuron Vulnerability via SLC17A7 Downregulation](/hypothesis/h-seaad-7f15df4c) — 0.63 · Target: SLC17A7
[Lysosomal Membrane Repair Enhancement](/hypothesis/h-8986b8af) — 0.59 · Target: CHMP2B
[Mitochondrial-Lysosomal Contact Site Engineering](/hypothesis/h-0791836f) — 0.59 · Target: RAB7A

Related Analyses:

[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
[Astrocyte reactivity subtypes in neurodegeneration](/analysis/SDA-2026-04-01-gap-007) 🔄
[Lipid raft composition changes in synaptic neurodegeneration](/analysis/SDA-2026-04-01-gap-lipid-rafts-2026-04-01) 🔄
[TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
[Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) 🔄

📖 View canonical wiki page →

Section 253: Respiratory Function and Dysphagia Therapy in CBS/PSP

Section 253: Respiratory Function and Dysphagia Therapy in CBS/PSP

Overview

Section 253: Respiratory Function and Dysphagia Therapy in CBS/PSP

Overview

1. Pathophysiology of Respiratory and Swallowing Dysfunction in CBS/PSP

1.1 Neuroanatomical Basis

1.2 Swallowing Phases Affected

1.3 Respiratory-Swallow Coordination

2. Assessment of Respiratory and Swallowing Function

2.1 Clinical Bedside Assessment

2.2 Instrumental Assessment

2.3 Aspiration Risk Stratification

3. Therapeutic Interventions for Dysphagia

3.1 Compensatory Strategies

3.2 Swallow Rehabilitation

3.3 Pharmacological Approaches

4. Respiratory Therapy and Pulmonary Care

4.1 Respiratory Muscle Training

4.2 Cough Augmentation

4.3 Non-Invasive Ventilation (NIV)

4.4 Secretion Management

5. Aspiration Pneumonia Prevention

5.1 Risk Factor Modification

5.2 Oral Hygiene

5.3 Vaccination

6. Enteral Nutrition Considerations

6.1 Timing of Feeding Tube Placement

6.2 Tube Feeding Options

6.3 Tube Feeding Protocol

7. Clinical Trials and Emerging Therapies

7.1 Active Trials in Respiratory/Dysphagia for PSP

7.2 Emerging Interventions

8. Integrated Management Protocol

8.1 Assessment Schedule

8.2 Escalation Pathway

8.3 Multidisciplinary Team

9. Quality of Life and Caregiver Considerations

9.1 Impact on Quality of Life

9.2 Caregiver Support

9.3 End-of-Life Considerations

10. Cross-Links to Related Topics

References

Related Hypotheses